Physician profile
Christopher Mendello
NPI 1750322384
$8,184.51
in general payments reported to CMS, 2019-2025
41 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $726 · 2021: $1,129 · 2022: $1,157 · 2023: $1,473 · 2024: $1,552 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,335 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,334.78 |
| Education | $126.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $1,247.56 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $1,224.11 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $737.27 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.44 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $455.82 | 2020-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $390.95 | 2019-2025 | Zerbaxa, Recarbrio, Verquvo |
| Regeneron Healthcare Solutions, INC. | $383.97 | 2021-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $373.42 | 2019-2025 | |
| Philips North America LLC | $268.11 | 2019-2025 | Vest Therapy Und |
| Genzyme Corporation | $236.06 | 2019-2025 | |
| Advanced Respiratory, INC | $200.53 | 2019-2021 | |
| Axsome Therapeutics, INC. | $192.07 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $177.94 | 2023-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $162.67 | 2019-2025 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $155.23 | 2024-2025 | Inspire |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $147.03 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mylan Specialty L.P. | $133.09 | 2019-2023 | Yupelri |
| Inogen, INC. | $130.25 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $130.00 | 2020-2024 | Nuzyra |
| Grifols USA, LLC | $99.48 | 2019-2024 | Prolastin-C Liquid |
| Resmed Corp | $88.03 | 2019-2025 | |
| Melinta Therapeutics, LLC | $85.32 | 2023 | Vabomere, Orbactiv, Kimyrsa |
| Eisai INC. | $84.26 | 2020-2022 | |
| Abbvie INC. | $74.38 | 2022-2023 | |
| Amgen INC. | $64.00 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $62.68 | 2022-2023 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Verona Pharma, INC. | $59.35 | 2025 | Ohtuvayre |
| Shionogi INC | $41.05 | 2023 | Fetroja |
| Fisher & Paykel Healthcare INC | $40.02 | 2024 | Fisher & Paykel Healthcare |
| Circassia INC. | $31.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.18 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $24.17 | 2023 | |
| Sunovion Pharmaceuticals INC. | $17.76 | 2019 | |
| Smith+Nephew, INC. | $17.43 | 2023 | Pico |
| Cumberland Pharmaceuticals, INC. | $17.43 | 2023 | Vibativ |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2021 | |
| Lilly USA, LLC | $16.57 | 2025 | Zepbound |
| Chiesi USA, INC. | $16.08 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.95 | 2023 | Quviviq |
| Electromed, INC. | $14.07 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mendello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.